Jefferies Group’s AnaptysBio ANAB Stock Holding History

Jefferies Group’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-53,400	Closed	-$5.33M	–	2135
2018 Q3	$5.33M	Buy	+53,400	New	+$4.43M	0.03%	510

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Jefferies Group's ANAB Position: Q2 2021 in Review

Jefferies Group sold out of AnaptysBio (ANAB) in Q2 2021, closing a stake of 5,710 shares — an estimated $123K sold.

Jefferies Group first reported a position in ANAB in Q3 2019 and held it in 5 quarters. The position peaked at $488K in Q4 2019. 122 funds tracked by Wall St. Rank hold ANAB as of Q2 2021.

Jefferies Group reported no remaining AnaptysBio position as of Q2 2021 after selling out during the quarter.
Jefferies Group sold 5,710 AnaptysBio shares in Q2 2021, an estimated $123K.
Jefferies Group first reported a position in AnaptysBio in Q3 2019 and held it in 5 quarters.
Jefferies Group's AnaptysBio position peaked at $488K in Q4 2019.
122 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.